15 September 2020 in Science Signaling
PD-1 signaling suppresses tumor-infiltrating lymphocytes by destabilizing their interactions with target tumor cells.
3 December 2023 in European Journal of Immunology
Vaccination is considered one of the major milestones in modern medicine, facilitating the control and eradication of life‐threatening infectious diseases. Vaccine adjuvants are a key component of many vaccines, serving to steer antigen‐specific immune responses and increase their magnitude. Despite major advances in the field of adjuvant research over recent decades, our understanding of their mechanism of action remains incomplete. This hinders our capacity to further improve these adjuvant technologies, so addressing how adjuvants induce and control the induction of innate and adaptive immunity is a priority. Investigating how adjuvant physicochemical properties, such as size and charge, exert immunomodulatory effects can provide valuable insights and serve as the foundation for the rational design of vaccine adjuvants. Most clinically applied adjuvants are particulate in nature and polymeric particulate adjuvants present advantages due to stability, biocompatibility profiles, and flexibility in terms of formulation. These properties can impact on antigen release kinetics and biodistribution, cellular uptake and targeting, and drainage to the lymphatics, consequently dictating the induction of innate, cellular, and humoral adaptive immunity. A current focus is to apply rational design principles to the development of adjuvants capable of eliciting robust cellular immune responses including CD8+ cytotoxic T‐cell and Th1‐biased CD4+ T‐cell responses, which are required for vaccines against intracellular pathogens and cancer. This review highlights recent advances in our understanding of how particulate adjuvants, especially polymer‐based particulates, modulate immune responses and how this can be used as a guide for improved adjuvant design.
4 August 2025 in Immunology & Cell Biology
Tumor rejection is primarily mediated by cytotoxic T cells, making them critical targets for therapeutic cancer vaccines. Vaccine adjuvants can modulate innate immunity, influencing adaptive immune responses. For particulate adjuvants, such as polymeric nanoparticles, physicochemical properties—including size, charge, composition and antigen location within the formulation—can shape these responses. Free‐soluble antigens typically fail to induce sufficient dendritic cell maturation and cross‐presentation needed for robust CD8+ T‐cell activation. However, this can be enhanced by delivering antigen with nanoparticles of appropriate size. While adjuvants like oil‐in‐water emulsions do not require antigen association for vaccine efficacy, the importance of antigen location in the adjuvanticity of polymeric nanoparticles is less clear. We demonstrate that colocalization of antigen and polymeric nanoparticles through antigen adsorption enhances proliferation and activation of antigen‐specific CD8+ T cells following intramuscular vaccination. While type 1 conventional dendritic cells (cDC1) can prime CD8+ T cells in other settings, their requirement with polymeric nanoparticles has not been fully addressed. We show that nanoparticle‐induced CD8+ T‐cell responses rely on cDC1s. The therapeutic efficacy of a polymeric nanoparticle vaccine was significantly enhanced when antigen was adsorbed on nanoparticles, leading to reduced tumor growth and prolonged survival in mice challenged with immunologically hot (MC38) and cold (B16F10) tumors expressing ovalbumin. Furthermore, vaccination with nanoparticle‐adsorbed antigen synergized with anti‐PD‐1 checkpoint blockade, enhancing protection, especially against B16F10‐ovalbumin tumors. This work highlights the role of antigen association with polymeric nanoparticles in eliciting CD8+ T‐cell responses for the development of effective therapeutic cancer vaccines.
2 March 2023 in Nature Materials
A polymeric nanoparticle adjuvant containing a Toll-like receptor 7 agonist elicits broad protection against viral challenges.